
PRME Stock Forecast & Price Target
PRME Analyst Ratings
Bulls say
Prime Medicine is attractive fundamentally because its pipeline is beginning to convert a broad prime-editing platform into multiple, liver-targeted clinical programs with clear catalysts, including PM577a in Wilson disease and PM647 in AATD, both with initial data expected in 2027. The company also has meaningful external validation from PM359 in CGD, where human data showed durable restoration of immune function, and it retains additional upside from a potential PM359 BLA submission in 1H27 and a possible PRV that could monetize at roughly $200M based on recent sales. Financially, 3Q26 collaboration revenue was $4.2M, net loss was $0.22 per share, and the November offering lifted pro forma liquidity to about $209.5M, which management expects to fund operations through 2027 and reduces near-term dilution risk.
Bears say
Prime Medicine is viewed negatively because its $109 mm cash balance as of 30 June, down from $191.4M at end-FY25, appears only sufficient to fund two programs into 2027 while high cash burn keeps financing risk elevated. The outlook is further pressured by substantial clinical and regulatory uncertainty, including patient recruitment hurdles, gene-editing safety concerns, and no certainty of approval or reimbursement in the US or elsewhere. Commercially, Wilson disease, AATD, and cystic fibrosis face competition and may not be as large as expected, while the company may still need additional capital before profitability, risking dilution.
This aggregate rating is based on analysts' research of Prime Medicine Inc and is not a guaranteed prediction by Public.com or investment advice.
PRME Analyst Forecast & Price Prediction
Start investing in PRME
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About Prime Medicine Inc (PRME) Forecast
PRME Analyst Forecast & Price Prediction
Start investing in PRME
Order type
Buy in
Order amount
Est. shares
0 shares